Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, August 19, 2022; Inify Laboratories AB ("Inify") has been notified that the following transaction has been completed by a close associate to a primary insider in Inify: Monsun AS, a Norwegian company controlled by Magne Jordanger, board member and primary insider in Inify, has bought 336,950 shares in Inify at an average price of NOK 7.6 per share. After the transaction, Monsun AS holds 336,950 shares. Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements in the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact CEO Fredrik Palm (fredrik.palm@inify.com) or visit www.inify.com

About Inify Laboratories AB (publ)

Inify Laboratories provides cancer diagnostics through ultra-modern laboratory services within histopathology. Fully digital, standardized and AI- supported workflow is applied to optimize quality and response times, initially for prostate cancer. The concept is scalable and extendible to other diagnosis. The company origins from ContextVision and became independent in February 2022. The company is based in Sweden and listed on Euronext Growth Oslo under the ticker INIFY